quinolinic acid has been researched along with Degenerative Diseases, Central Nervous System in 38 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Quinolinic acid is an N-methyl-D-aspartate receptor agonist, and raised levels in CSF, together with increased levels of inflammatory cytokines, have been reported in mood disorders." | 6.82 | The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases. ( Aaseth, JO; Alexander, J; Hestad, K; Rootwelt, H, 2022) |
| "Low-grade inflammation is common in obesity, but the mechanism between inflammation and cognitive impairment in obesity is unclear." | 5.91 | Butyrate ameliorates quinolinic acid-induced cognitive decline in obesity models. ( Fang, X; Ge, X; Geng, D; Guan, L; Hu, M; Huang, XF; Liu, S; Pan, W; Tang, R; Wang, L; Xie, Y; Yu, Y; Zhang, J; Zheng, K; Zheng, M; Zheng, P; Zhou, L; Zhou, M, 2023) |
| "There has been considerable scientific effort dedicated to understanding the biologic consequence and therapeutic implications of aberrant tryptophan metabolism in brain tumors and neurodegenerative diseases." | 4.31 | Quinolinate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR/PPARγ signaling axis. ( Buelow, KL; Chinnaiyan, P; Kant, S; Kesarwani, P; Miller, CR; Prabhu, A; Zhao, Y, 2023) |
| "Increased accumulation of endogenous neurotoxin quinolinic acid has been found in various neurodegenerative diseases." | 3.88 | Asiatic acid prevents the quinolinic acid-induced oxidative stress and cognitive impairment. ( Loganathan, C; Thayumanavan, P, 2018) |
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| "Quinolinic acid is an N-methyl-D-aspartate receptor agonist, and raised levels in CSF, together with increased levels of inflammatory cytokines, have been reported in mood disorders." | 2.82 | The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases. ( Aaseth, JO; Alexander, J; Hestad, K; Rootwelt, H, 2022) |
| "Adenosine is an ubiquitous purine that can protect neurons by suppressing excitatory neurotransmitter release, reducing calcium fluxes and inhibiting NMDA receptors." | 2.44 | Tryptophan, adenosine, neurodegeneration and neuroprotection. ( Darlington, LG; Forrest, CM; Mackay, GM; Stone, TW; Stoy, N, 2007) |
| "L-kynurenine is a central compound of this pathway since it can change to the neuroprotective agent kynurenic acid or to the neurotoxic agent quinolinic acid." | 2.43 | Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. ( Németh, H; Toldi, J; Vécsei, L, 2006) |
| "Low-grade inflammation is common in obesity, but the mechanism between inflammation and cognitive impairment in obesity is unclear." | 1.91 | Butyrate ameliorates quinolinic acid-induced cognitive decline in obesity models. ( Fang, X; Ge, X; Geng, D; Guan, L; Hu, M; Huang, XF; Liu, S; Pan, W; Tang, R; Wang, L; Xie, Y; Yu, Y; Zhang, J; Zheng, K; Zheng, M; Zheng, P; Zhou, L; Zhou, M, 2023) |
| "EDA is a molecule approved for the treatment of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease associated with an increase of QUIN concentrations in both serum and cerebrospinal fluid." | 1.72 | Chromatographic measurement of 3-hydroxyanthranilate 3,4-dioxygenase activity reveals that edaravone can mitigate the formation of quinolinic acid through a direct enzyme inhibition. ( Altomare, A; Mercolini, L; Mondanelli, G; Protti, M; Regazzoni, L; Sanz, I; Valsecchi, V; Volpi, C, 2022) |
| "Quinolinic acid (QUIN) is an agonist of the neurotransmitter glutamate (Glu) capable of binding to N-methyl-D-aspartate receptors (NMDAR) increasing glutamatergic signaling." | 1.62 | Caenorhabditis elegans as a model for studies on quinolinic acid-induced NMDAR-dependent glutamatergic disorders. ( Antunes Soares, FA; Aschner, M; Bicca Obetine Baptista, F; Duarte Hartmann, D; Farina Gonçalves, D; Franzen da Silva, A; Lenz Dalla Corte, C; Limana da Silveira, T; Lopes Machado, M; Marafiga Cordeiro, L, 2021) |
| "Quinolinic acid (QUIN) is an endogenous neurotoxin that acts as an N-methyl-D-aspartate receptor (NMDAR) agonist generating a toxic cascade, which can lead to neurodegeneration." | 1.48 | Quinolinic acid and glutamatergic neurodegeneration in Caenorhabditis elegans. ( Arantes, LP; Aschner, M; Câmara, DF; da Silva, TC; da Silveira, TL; Machado, ML; Santamaría, A; Soares, FAA; Zamberlan, DC, 2018) |
| "Treatment with rosiglitazone (5, 10 mg/kg) and VPA (100, 200 mg/kg) for 21 days significantly attenuated these behavioral, biochemical, and cellular alterations as compared to control (QA 200 nmol) group." | 1.40 | Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways. ( Chaudhary, T; Kumar, A; Mishra, J, 2014) |
| "Quinolinic acid (QUIN) was used as a typical excitotoxic/pro-oxidant inducer, 3-nitropropionic acid (3-NP) was employed as a mitochondrial function inhibitor, and their combination (QUIN + 3-NP) was also evaluated in in vitro studies." | 1.36 | Antioxidant strategy to rescue synaptosomes from oxidative damage and energy failure in neurotoxic models in rats: protective role of S-allylcysteine. ( Elinos-Calderón, D; Galván-Arzate, S; Maldonado, PD; Pedraza-Chaverrí, J; Pérez-De La Cruz, V; Robledo-Arratia, Y; Santamaría, A, 2010) |
| "A transgenic mouse model of Huntington's disease (R6/1 and R6/2 lines) expressing exon 1 of the HD gene with 115-150 CAG repeats resisted striatal damage following injection of quinolinic acid and other neurotoxins." | 1.31 | Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. ( Aronin, N; Brundin, P; Chase, K; DiFiglia, M; Petersén, A; Puschban, Z, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.63) | 18.2507 |
| 2000's | 13 (34.21) | 29.6817 |
| 2010's | 18 (47.37) | 24.3611 |
| 2020's | 6 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Bongarzone, S | 1 |
| Savickas, V | 1 |
| Luzi, F | 1 |
| Gee, AD | 1 |
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Hestad, K | 1 |
| Alexander, J | 1 |
| Rootwelt, H | 1 |
| Aaseth, JO | 1 |
| Sanz, I | 1 |
| Altomare, A | 1 |
| Mondanelli, G | 1 |
| Protti, M | 1 |
| Valsecchi, V | 1 |
| Mercolini, L | 1 |
| Volpi, C | 1 |
| Regazzoni, L | 1 |
| Ge, X | 1 |
| Zheng, M | 1 |
| Hu, M | 1 |
| Fang, X | 1 |
| Geng, D | 1 |
| Liu, S | 1 |
| Wang, L | 1 |
| Zhang, J | 1 |
| Guan, L | 1 |
| Zheng, P | 1 |
| Xie, Y | 1 |
| Pan, W | 1 |
| Zhou, M | 1 |
| Zhou, L | 1 |
| Tang, R | 1 |
| Zheng, K | 1 |
| Yu, Y | 1 |
| Huang, XF | 1 |
| Kesarwani, P | 1 |
| Kant, S | 1 |
| Zhao, Y | 1 |
| Prabhu, A | 1 |
| Buelow, KL | 1 |
| Miller, CR | 1 |
| Chinnaiyan, P | 1 |
| Limana da Silveira, T | 1 |
| Lopes Machado, M | 1 |
| Bicca Obetine Baptista, F | 1 |
| Farina Gonçalves, D | 1 |
| Duarte Hartmann, D | 1 |
| Marafiga Cordeiro, L | 1 |
| Franzen da Silva, A | 1 |
| Lenz Dalla Corte, C | 1 |
| Aschner, M | 2 |
| Antunes Soares, FA | 1 |
| Parasram, K | 1 |
| Loganathan, C | 1 |
| Thayumanavan, P | 1 |
| da Silveira, TL | 1 |
| Zamberlan, DC | 1 |
| Arantes, LP | 1 |
| Machado, ML | 1 |
| da Silva, TC | 1 |
| Câmara, DF | 1 |
| Santamaría, A | 6 |
| Soares, FAA | 1 |
| Emerich, DF | 1 |
| Kordower, JH | 1 |
| Chu, Y | 1 |
| Thanos, C | 1 |
| Bintz, B | 1 |
| Paolone, G | 1 |
| Wahlberg, LU | 1 |
| Liu, P | 1 |
| Li, Y | 1 |
| Qi, X | 1 |
| Xu, J | 1 |
| Liu, D | 1 |
| Ji, X | 1 |
| Chi, T | 1 |
| Liu, H | 1 |
| Zou, L | 1 |
| Ignarro, RS | 1 |
| Vieira, AS | 1 |
| Sartori, CR | 1 |
| Langone, F | 1 |
| Rogério, F | 1 |
| Parada, CA | 1 |
| Tronel, C | 1 |
| Rochefort, GY | 1 |
| Arlicot, N | 1 |
| Bodard, S | 1 |
| Chalon, S | 1 |
| Antier, D | 1 |
| Lugo-Huitrón, R | 1 |
| Ugalde Muñiz, P | 1 |
| Pineda, B | 1 |
| Pedraza-Chaverrí, J | 4 |
| Ríos, C | 1 |
| Pérez-de la Cruz, V | 3 |
| Vallerini, GP | 1 |
| Amori, L | 1 |
| Beato, C | 1 |
| Tararina, M | 1 |
| Wang, XD | 1 |
| Schwarcz, R | 1 |
| Costantino, G | 1 |
| Mishra, J | 1 |
| Chaudhary, T | 1 |
| Kumar, A | 1 |
| Santana-Martínez, RA | 1 |
| Galván-Arzáte, S | 2 |
| Hernández-Pando, R | 1 |
| Chánez-Cárdenas, ME | 1 |
| Avila-Chávez, E | 1 |
| López-Acosta, G | 1 |
| Maldonado, PD | 3 |
| Serratos, IN | 1 |
| Castellanos, P | 1 |
| Pastor, N | 1 |
| Millán-Pacheco, C | 1 |
| Rembao, D | 1 |
| Pérez-Montfort, R | 1 |
| Cabrera, N | 1 |
| Reyes-Espinosa, F | 1 |
| Díaz-Garrido, P | 1 |
| López-Macay, A | 1 |
| Martínez-Flores, K | 1 |
| López-Reyes, A | 1 |
| Sánchez-García, A | 1 |
| Cuevas, E | 1 |
| Ayyappan, P | 1 |
| Palayyan, SR | 1 |
| Kozhiparambil Gopalan, R | 1 |
| Zádori, D | 1 |
| Klivényi, P | 1 |
| Vámos, E | 1 |
| Fülöp, F | 1 |
| Toldi, J | 2 |
| Vécsei, L | 3 |
| Elinos-Calderón, D | 1 |
| Robledo-Arratia, Y | 1 |
| Carmona-Ramírez, I | 1 |
| Tobón-Velasco, JC | 1 |
| Orozco-Ibarra, M | 1 |
| González-Herrera, IG | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Plangar, I | 1 |
| Szalardy, L | 1 |
| Rite, I | 1 |
| Venero, JL | 1 |
| Tomás-Camardiel, M | 1 |
| Machado, A | 1 |
| Cano, J | 1 |
| Tebano, MT | 2 |
| Pintor, A | 2 |
| Frank, C | 2 |
| Domenici, MR | 2 |
| Martire, A | 1 |
| Pepponi, R | 1 |
| Potenza, RL | 2 |
| Grieco, R | 1 |
| Popoli, P | 3 |
| Ganzella, M | 1 |
| Jardim, FM | 1 |
| Boeck, CR | 1 |
| Vendite, D | 1 |
| Németh, H | 1 |
| Minghetti, L | 1 |
| Greco, A | 1 |
| Pezzola, A | 2 |
| Blum, D | 1 |
| Bantubungi, K | 1 |
| Stone, TW | 1 |
| Forrest, CM | 1 |
| Mackay, GM | 1 |
| Stoy, N | 1 |
| Darlington, LG | 1 |
| Silva-Adaya, D | 1 |
| Herrera-Mundo, MN | 1 |
| Mendoza-Macedo, K | 1 |
| Villeda-Hernández, J | 1 |
| Binienda, Z | 1 |
| Ali, SF | 1 |
| Noack, H | 1 |
| Lindenau, J | 1 |
| Rothe, F | 1 |
| Asayama, K | 1 |
| Wolf, G | 1 |
| Nakai, M | 1 |
| Qin, Z | 1 |
| Wang, Y | 1 |
| Chase, TN | 1 |
| Ghorayeb, I | 1 |
| Puschban, Z | 2 |
| Fernagut, PO | 1 |
| Scherfler, C | 1 |
| Rouland, R | 1 |
| Wenning, GK | 1 |
| Tison, F | 1 |
| Kuroki, Y | 1 |
| Fukushima, K | 1 |
| Kanda, Y | 1 |
| Mizuno, K | 1 |
| Watanabe, Y | 1 |
| Scarchilli, L | 1 |
| Quarta, D | 1 |
| Reggio, R | 1 |
| Malchiodi-Albedi, F | 1 |
| Falchi, M | 1 |
| Massotti, M | 1 |
| Petersén, A | 1 |
| Chase, K | 1 |
| DiFiglia, M | 1 |
| Brundin, P | 1 |
| Aronin, N | 1 |
9 reviews available for quinolinic acid and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus; Drug Discovery; Glycation End Products, Advance | 2017 |
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases.
Topics: Cytokines; Humans; Kynurenine; Neurodegenerative Diseases; Quinolinic Acid; Tryptophan | 2022 |
Phytochemical treatments target kynurenine pathway induced oxidative stress.
Topics: Animals; Disease Models, Animal; Glutamic Acid; Humans; Kynurenine; Neurodegenerative Diseases; Neur | 2018 |
Quinolinic acid: an endogenous neurotoxin with multiple targets.
Topics: Animals; Energy Metabolism; Humans; Inflammation; Neurodegenerative Diseases; Neurotoxins; Oxidative | 2013 |
Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies.
Topics: Animals; Brain; Glutamic Acid; Humans; Kynurenic Acid; Mitochondrial Diseases; NAD; Neurodegenerativ | 2009 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.
Topics: Animals; Humans; Kynurenine; Neurodegenerative Diseases; Parkinson Disease; Quinolinic Acid; Recepto | 2006 |
Tryptophan, adenosine, neurodegeneration and neuroprotection.
Topics: Adenosine; Animals; Hepatic Encephalopathy; Humans; Kynurenine; NAD; Neurodegenerative Diseases; Neu | 2007 |
29 other studies available for quinolinic acid and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Chromatographic measurement of 3-hydroxyanthranilate 3,4-dioxygenase activity reveals that edaravone can mitigate the formation of quinolinic acid through a direct enzyme inhibition.
Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; 3-Hydroxyanthranilic Acid; Amyotrophic Lateral Sclerosis; Eda | 2022 |
Butyrate ameliorates quinolinic acid-induced cognitive decline in obesity models.
Topics: Animals; Brain-Derived Neurotrophic Factor; Butyrates; Cognitive Dysfunction; Humans; Inflammation; | 2023 |
Quinolinate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR/PPARγ signaling axis.
Topics: Animals; Biological Products; Brain Neoplasms; Glioblastoma; Immune Tolerance; Macrophages; Mice; Ne | 2023 |
Caenorhabditis elegans as a model for studies on quinolinic acid-induced NMDAR-dependent glutamatergic disorders.
Topics: 1-Octanol; Adenosine Triphosphate; Amino Acid Metabolism, Inborn Errors; Animals; Animals, Genetical | 2021 |
Asiatic acid prevents the quinolinic acid-induced oxidative stress and cognitive impairment.
Topics: Animals; Antioxidants; Cognition; Cognitive Dysfunction; Lipid Peroxidation; Male; Neurodegenerative | 2018 |
Quinolinic acid and glutamatergic neurodegeneration in Caenorhabditis elegans.
Topics: Animals; Animals, Genetically Modified; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Dos | 2018 |
Widespread Striatal Delivery of GDNF from Encapsulated Cells Prevents the Anatomical and Functional Consequences of Excitotoxicity.
Topics: Animals; Cell Encapsulation; Cell Line; Corpus Striatum; Drug Delivery Systems; Glial Cell Line-Deri | 2019 |
Protein kinase C is involved in the neuroprotective effect of berberine against intrastriatal injection of quinolinic acid-induced biochemical alteration in mice.
Topics: Animals; Berberine; Cognitive Dysfunction; Disease Models, Animal; Glutamic Acid; Glycogen Synthase | 2019 |
JAK2 inhibition is neuroprotective and reduces astrogliosis after quinolinic acid striatal lesion in adult mice.
Topics: Animals; Astrocytes; Blotting, Western; Cell Count; Cell Death; Doublecortin Domain Proteins; Enzyme | 2013 |
Oxidative stress is related to the deleterious effects of heme oxygenase-1 in an in vivo neuroinflammatory rat model.
Topics: Animals; Apoptosis; Brain; Disease Models, Animal; Ferrous Compounds; Heme Oxygenase-1; Hemin; Iron | 2013 |
2-Aminonicotinic acid 1-oxides are chemically stable inhibitors of quinolinic acid synthesis in the mammalian brain: a step toward new antiexcitotoxic agents.
Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; Animals; Brain; Cyclic N-Oxides; Disease Models, Animal; Drug | 2013 |
Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.
Topics: Animals; Body Weight; Brain; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; | 2014 |
Sulforaphane reduces the alterations induced by quinolinic acid: modulation of glutathione levels.
Topics: Animals; Anticarcinogenic Agents; Glutathione; Glutathione Reductase; Isothiocyanates; Lipid Peroxid | 2014 |
Modeling the interaction between quinolinate and the receptor for advanced glycation end products (RAGE): relevance for early neuropathological processes.
Topics: Animals; Brain; Male; Molecular Docking Simulation; Neurodegenerative Diseases; Oxidative Stress; Pr | 2015 |
Attenuation of Oxidative Damage by Boerhaavia diffusa L. Against Different Neurotoxic Agents in Rat Brain Homogenate.
Topics: Animals; Antioxidants; Brain; DNA Damage; Edetic Acid; Ferrous Compounds; Free Radicals; Lipid Perox | 2016 |
Antioxidant strategy to rescue synaptosomes from oxidative damage and energy failure in neurotoxic models in rats: protective role of S-allylcysteine.
Topics: Animals; Antioxidants; Brain; Corpus Striatum; Cysteine; Disease Models, Animal; Dyskinesia, Drug-In | 2010 |
RETRACTED: Curcumin restores Nrf2 levels and prevents quinolinic acid-induced neurotoxicity.
Topics: Animals; Corpus Striatum; Curcumin; Glutathione Peroxidase; Male; Neurodegenerative Diseases; Neurot | 2013 |
Manipulation with kynurenines: a possible tool for treating neurodegenerative diseases?
Topics: Animals; Drug Design; Humans; Kynurenic Acid; Kynurenine; Neurodegenerative Diseases; Quinolinic Aci | 2012 |
Expression of BDNF mRNA in substantia nigra is dependent on target integrity and independent of neuronal activation.
Topics: Animals; Axonal Transport; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Colchicine; Female; K | 2003 |
Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum.
Topics: 4-Aminopyridine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Calcium; Corpus Striatum; Do | 2004 |
Time course of oxidative events in the hippocampus following intracerebroventricular infusion of quinolinic acid in mice.
Topics: AIDS Dementia Complex; Animals; Antioxidants; Cells, Cultured; Disease Models, Animal; Encephalitis; | 2006 |
Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration.
Topics: Adenosine A2 Receptor Antagonists; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Cycl | 2007 |
Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of L-carnitine.
Topics: Animals; Antioxidants; Brain; Carnitine; Convulsants; Disease Models, Animal; Dose-Response Relation | 2008 |
Differential expression of superoxide dismutase isoforms in neuronal and glial compartments in the course of excitotoxically mediated neurodegeneration: relation to oxidative and nitrergic stress.
Topics: Animals; Ascorbic Acid; Brain; Cell Compartmentation; Cytosol; Dehydroascorbic Acid; Isoenzymes; Mal | 1998 |
NMDA and non-NMDA receptor-stimulated IkappaB-alpha degradation: differential effects of the caspase-3 inhibitor DEVD.CHO, ethanol and free radical scavenger OPC-14117.
Topics: Animals; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Central Nervous System Depressants; Cor | 2000 |
Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration.
Topics: Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal; Forelimb; Male; Micr | 2001 |
Neuroprotection by estrogen via extracellular signal-regulated kinase against quinolinic acid-induced cell death in the rat hippocampus.
Topics: Animals; Butadienes; Cell Death; Enzyme Inhibitors; Estradiol; Extracellular Space; Hippocampus; Inj | 2001 |
Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.
Topics: Animals; Behavior, Animal; Calcium; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dose-R | 2002 |
Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.
Topics: Animals; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Disease Susceptibility; He | 2002 |